My Cart

ADAM17

ADAM17 Overview

English NameDisintegrin and metalloproteinase domain-containing protein 17Approved Drugs0
Drugs in Clinical Trials2Target SynonymEC:3.4.24.86,ADAM17 Protein,ADAM 17,Snake venom-like protease,CSVP,CD156b,ADAM17,ADAM Metallopeptidase Domain 17,TNF-Alpha Convertase,TACE,TNF-Alpha Converting Enzyme,TNF-Alpha-Converting Enzyme,CD156b Antigen,EC 3.4.24.86,NISBD1,NISBD,Disintegrin and metalloproteinase domain-containing protein 17,Tumor Necrosis Factor, Alpha, Converting Enzyme,ADAM Metallopeptidase Domain 18,ADAM18
Highest Development StagePhase 1 Clinical
English NameDisintegrin and metalloproteinase domain-containing protein 17
Target SynonymEC:3.4.24.86,ADAM17 Protein,ADAM 17,Snake venom-like protease,CSVP,CD156b,ADAM17,ADAM Metallopeptidase Domain 17,TNF-Alpha Convertase,TACE,TNF-Alpha Converting Enzyme,TNF-Alpha-Converting Enzyme,CD156b Antigen,EC 3.4.24.86,NISBD1,NISBD,Disintegrin and metalloproteinase domain-containing protein 17,Tumor Necrosis Factor, Alpha, Converting Enzyme,ADAM Metallopeptidase Domain 18,ADAM18
Approved Drugs0
Drugs in Clinical Trials2
Highest Development StagePhase 1 Clinical

ADAM17 Product List

  • Product Category

    Protein (2)

  • Product Status

    Launched (2)

  • Species

    Mouse (1)Human (1)

  • Tag

    His Tag (2)

  • Conjugate

    Unconjugated (2)

Cat. No.SpeciesHostProduct DescriptionStructurePurityFeatureOrder Now
AD7-H53H3
Human
CHO
Human ADAM17 / TACE / CD156b Protein, His Tag (active enzyme)
Add to Cart
AD7-M52H1
Mouse
HEK293
Mouse ADAM17 / TACE / CD156b Protein, His Tag
Add to Cart
Total: 2
  • 1

ADAM17 Background

Disintegrin and metalloproteinase domain-containing protein 17 (ADAM17), a member of the ADAM protein family of disintegrins and metalloproteases, is also known as TNF-alpha convertase, TNF-alpha-converting enzyme and CD156b, which contains one disintegrin domain and one peptidase M12B domain. ADAM17 can cleave the membrane-bound precursor of TNF-alpha to its mature soluble form. ADAM17 is also responsible for the proteolytical release of soluble JAM3 from endothelial cells surface (By similarity) and proteolytic release of several other cell-surface proteins, including p75 TNF-receptor, interleukin 1 receptor type II, p55 TNF-receptor, transforming growth factor-alpha, L-selectin, growth hormone receptor, MUC1 and the amyloid precursor protein. Furthermore, ADAM17 acts as an activator of Notch pathway by mediating cleavage of Notch, generating the membrane-associated intermediate fragment called Notch extracellular truncation.

ADAM17 Synonyms

ADAM17,TACE,CD156b

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
AderbasibINCB-7839; INC-B007839; INCB-007839Phase 1 ClinicalIncyte CorpSolid tumours; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Glioblastoma; Oligodendroglioma; Breast Neoplasms; Astrocytoma; Diffuse Intrinsic Pontine Glioma; Glioma
Details
ORYN-1001ORTD-1; ORYN-1001Phase 1 ClinicalOryn Therapeutics LlcCoronavirus Disease 2019 (COVID-19); Arthritis, Rheumatoid
Details
  • Overview
  • Product List
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland